Generex Biotechnology Corporation
GNBTQ
OTC PK
| 04/30/2021 | 01/31/2021 | 10/31/2020 | 07/31/2020 | 04/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -65.83% | -55.34% | -61.05% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -65.83% | -55.34% | -61.05% | -- | -- |
| Cost of Revenue | -11.85% | -73.71% | -86.19% | -- | -- |
| Gross Profit | -79.38% | -28.54% | -13.64% | -- | -- |
| SG&A Expenses | 29.57% | 12.02% | -3.92% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.88% | 14.34% | -9.13% | -- | -- |
| Operating Income | -49.20% | -21.37% | -0.78% | -- | -- |
| Income Before Tax | -40.52% | -60.73% | 6.10% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.52% | -60.73% | 6.10% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 31.99% | -50.36% | -45.06% | -- | -- |
| Net Income | -40.89% | -67.37% | 4.22% | -- | -- |
| EBIT | -49.20% | -21.37% | -0.78% | -- | -- |
| EBITDA | -49.48% | -20.92% | -0.59% | -- | -- |
| EPS Basic | 3.81% | -19.42% | 20.07% | -- | -- |
| Normalized Basic EPS | 36.74% | 9.47% | 32.94% | -- | -- |
| EPS Diluted | -24.06% | -17.38% | 19.82% | -- | -- |
| Normalized Diluted EPS | 33.80% | 9.47% | 32.94% | -- | -- |
| Average Basic Shares Outstanding | 54.67% | 36.24% | 20.11% | -- | -- |
| Average Diluted Shares Outstanding | 64.60% | 36.24% | 20.11% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
